Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCI-GULF
NCT07349979Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in ischemic cardiomyopathy (ICM), heart failure with reduced ejection fraction (HFrEF) and coronary artery disease (CAD) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Major adverse cardiovascular events at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Conditions
ischemic cardiomyopathy (ICM)heart failure with reduced ejection fraction (HFrEF)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07349979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349979.